Pepticom Company
"Novel Peptide Drug Candidates."
Pepticom aims to use artificial intelligence to streamline peptide drug discovery. The algorithmic platform combines principles from economic and molecular mechanics to generate a wide scope of active molecules with higher success rates. In so doing, Pepticom aims to lower the number of R&D candidates synthesized and tested with a similar reduction in time and costs when compared with traditional lab-based discovery methods.
The use of computational technology allows Pepticom to address complex targets unreachable by laboratory methods and to further enhance research and development. The platform utilizes the structure of the target protein to design innovative peptides at atomic resolution. It is capable of designing several peptides' chemistry, including linear, helical, and cyclic peptides, and to incorporate D and non-natural amino acids in the process.
The company is involved in various successful discovery projects with academic and industry partners and has several molecules in different R&D stages.
Pepticom is implementing its proprietary technology on various coronavirus proteins such as the ACE2 to identify novel peptide inhibitors that can fight COVID-19.
Combating Coronavirus Pandemic:
Pepticom's solution helps address the Coronavirus Pandemic. Pepticom aims to use artificial intelligence to streamline peptide drug discovery. It announced that it is implementing its tech on various coronavirus proteins to identify novel inhibitors that can fight the virus, and is looking for partners to validate and develop these drug candidates.
Pepticom aims to use artificial intelligence to streamline peptide drug discovery. The algorithmic platform combines principles from economic and molecular mechanics to generate a wide scope of active molecules with higher success rates. In so doing, Pepticom aims to lower the number of R&D candidates synthesized and tested with a similar reduction in time and costs when compared with traditional lab-based discovery methods.
The use of computational technology allows Pepticom to address complex targets unreachable by laboratory methods and to further enhance research and development. The platform utilizes the structure of the target protein to design innovative peptides at atomic resolution. It is capable of designing several peptides' chemistry, including linear, helical, and cyclic peptides, and to incorporate D and non-natural amino acids in the process.
The company is involved in various successful discovery projects with academic and industry partners and has several molecules in different R&D stages.
Pepticom is implementing its proprietary technology on various coronavirus proteins such as the ACE2 to identify novel peptide inhibitors that can fight COVID-19.
Combating Coronavirus Pandemic:
Pepticom's solution helps address the Coronavirus Pandemic. Pepticom aims to use artificial intelligence to streamline peptide drug discovery. It announced that it is implementing its tech on various coronavirus proteins to identify novel inhibitors that can fight the virus, and is looking for partners to validate and develop these drug candidates.
Technology:
COVID Treatments
Industry:
Treatment Development
Headquarters:
Israel
Founded Date:
2011
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership